-
Article
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium
The incidence and mortality of lung cancer in women are rising, with both increasing by 124% between 2003 and 2019. The main risk factor for lung cancer is tobacco use, but indoor radon gas exposure is one of ...
-
Article
Open AccessExpert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer
Lung cancer (LC) is associated with ageing, with the average age of affected individuals being approximately 70 years. However, despite a higher incidence and prevalence among older people, the older adult pop...
-
Article
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Therapeutic strategies harnessing the immune system to eliminate tumour cells have been successfully used for several cancer types, including in patients with advanced-stage non-small-cell lung cancer (NSCLC)....
-
Article
Open AccessA Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study
This Delphi panel study assessed the level of consensus between medical oncologists on the clinical management of patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC).
-
Article
Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?
Efforts are being made to incorporate immune-checkpoint inhibitors into therapy for early stage non-small-cell lung cancer. The IMpower010 trial of adjuvant atezolizumab has recently become the first study to ...
-
Article
Open AccessAssessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study
Little is known about the impact of sex on lung cancer patients from the psychological, economic and social perspectives. This study was designed to explore the psychosocial and economic impact according to se...
-
Article
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma
The aim of our study was to investigate the association between driver oncogene alterations and metastatic patterns on imaging assessment, in a large cohort of metastatic lung adenocarcinoma patients.
-
Article
Upfront osimertinib — winner takes it all?
The survival outcomes of the FLAURA trial support osimertinib as the new first-line standard of care for patients with EGFR-mutated advanced-stage non-small-cell lung cancer in health-care systems that can afford...
-
Article
In Search of the Long-Desired ‘Copernican Therapeutic Revolution’ in Small-Cell Lung Cancer
Small-cell lung cancer has defied our scientific community for decades. Chemotherapy has been the mainstay treatment for small-cell lung cancer (SCLC) and unlike its counterpart, non-small cell lung cancer, no...
-
Article
Open AccessErratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
-
Article
Open AccessSuccesses and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Immune checkpoint inhibitors have significantly modified the therapeutic landscape of advanced non-small cell lung cancer in second-line settings, with a more recent advancement in first-line settings. Given t...
-
Article
Open AccessThe epidermal growth factor receptor (EGRF) in lung cancer
In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal g...
-
Article
SEOM guidelines for the treatment of malignant pleural mesothelioma
Mesothelioma is a rare malignant tumour. Asbestos is the principal aetiological agent of malignant pleural mesothelioma (MPM) (∼80% of cases). The incidence of MPM is still increasing and will peak within the ...
